Funding to accelerate clinical advancement of VGA039, a pioneering antibody therapy for bleeding disorders, starting with von Willebrand Disease

GordonMD Global Investments^® today announced that it has participated in an oversubscribed $125 million Series D financing for Star Therapeutics, a clinical-stage biotechnology company discovering and developing novel antibodies for bleeding disorders and other diseases. GordonMD Global Investments^® is among Star’s new investors, underscoring the firm’s commitment to advancing transformative therapies in hematology.

The financing, co-led by Sanofi Ventures and Viking Global Investors, will fuel the continued advancement of Star’s pipeline, including its lead program, VGA039. VGA039 is a groundbreaking antibody that targets Protein S to restore balance in blood clotting. It is being developed as a universal therapy for bleeding disorders, starting with von Willebrand Disease (VWD). A pivotal Phase 3 trial of VGA039 in VWD patients is now underway.

“We are pleased to support Star Therapeutics as it advances VGA039 into late-stage clinical development,” said Dr. Craig Gordon, Founder and Chief Executive Officer of GordonMD Global Investments^®. “Star’s innovative approach has the potential to change the standard of care for patients with serious bleeding disorder.”

Adam Rosenthal, Ph.D., CEO and Founder of Star Therapeutics, added: “The addition of GordonMD Global Investments^® to our strong syndicate of life sciences investors reinforces the significance of our work and the broad enthusiasm for VGA039. This investment will help us continue to progress our pipeline as we work to deliver meaningful advances for patients with bleeding disorders.”

Star’s financing also included participation from Janus Henderson Investors, Frazier Life Sciences, and other existing backers.

About GordonMD Global Investments®

GordonMD Global Investments^® LP was founded in 2021 by Craig Gordon, MD, a licensed physician with more than 13 years of buy-side experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan. It currently provides investment management and administrative services to a hedge fund investing primarily in publicly traded companies as well as to two private equity funds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006080228/en/